Current Report Filing (8-k)
November 29 2017 - 2:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
November 27,
2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
|
Nevada
|
000-52138
|
20-2000871
|
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
|
incorporation)
|
|
Identification No.)
|
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code
(250)
765-6424
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d -2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
[ ]
|
Item 3.02
|
Unregistered Sales of Equity Securities
|
Lexaria has received US$118,913
from the exercise of
warrants and a compensation option certificate previously granted. The
compensation option certificate was exercised at the price of US$0.42. The stock
warrants were exercised at prices of US$0.14, US$0.273, and US$0.60, for a total
of 415,187 common shares being issued. All exercises are by third parties who
are neither officers nor directors of the Company. Following issuance of these common shares, Lexaria
will have 69,435,198 common shares issued and outstanding. No commissions or
placement fees have been paid related to the funds received from these warrants
exercised. Proceeds will be used for general corporate purposes.
- 2 -
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
Additionally, Lexaria is attending and delivering a
presentation at the upcoming 10
th
annual LD Micro Main Event on
December 5-7 located in Los Angeles and filing its annual 10K with Securities
and Exchange Commission.
|
Item 7.01
|
Regulation FD Disclosure
|
A copy of the news release announcing that Lexaria has received
US$118,913
from a warrant exercise previously granted is filed as exhibit
99.1 to this current report and is hereby incorporated by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
/s/ Chris
Bunka
|
|
|
Chris Bunka
|
|
|
CEO, Principal Executive Officer
|
|
Date: November 27, 2017